The efficacy and safety of photodynamic therapy for central serous chorioretinopathy

The efficacy and safety of photodynamic therapy for central serous chorioretinopathy - Photodynamic therapy for central serous chorioretinopathy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000022126

Enrollment

Registered

2016-06-01

Start date

2016-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Central serous chorioretinopathy

Interventions

3mg/m2 intravenous infusion of verteporfin over 10 minutes followed by delivery of laser at 15 minutes. Nonthermal laser light of 689nm wavelength is applied for 83 sec delivering a dose of 50J/cm2

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.3 months or more after onset 2.presence of active angiographic leakage under or adjacent to fovea in fluorescein angiography 3.presence of serous retinal detachment on optical coherence tomography 4.written informed consent

Exclusion criteria

Exclusion criteria: 1. drug allery to verteporfin 2. pregnant or expecting pregnancy 3. porphyria 4. macular diseases other than central serous chorioretinopathy 5. others (inappropriate case judged by investigator or subinvestigators)

Design outcomes

Primary

Measure	Time frame
Resolution of serous retinal detachment of 1week, 1month, 3months, 6months, and 1year after photodynamic therapy	—

Countries

Japan

Contacts

Public ContactNobuhiro Terao

Kyoto Prefectual Univercity of Medicine Department of Ophthalmology

nobu9124@koto.kpu-m.ac.jp075-251-5578

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026